Cartesian Therapeutics (RNAC) Cash from Financing Activities (2015 - 2026)
Cartesian Therapeutics (RNAC) posted quarterly Cash from Financing Activities of $15.7 million for Q1 2026, up 295.28% year-over-year from $4.0 million in Q1 2025, and up 30236.54% quarter-over-quarter from -$52000.0 in Q4 2025.
Powered by 
Analysis
Cartesian Therapeutics (RNAC) Cash from Financing Activities (2015 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has reported Cash from Financing Activities for 12 consecutive years, with $15.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 295.28% year-over-year to $15.7 million; the TTM figure through Mar 2026 stood at $15.6 million (down 86.67% YoY), while the FY2025 annual figure was -$8.1 million, down 104.78% from the prior year.
- Cash from Financing Activities grew to $15.7 million in Q1 2026 per RNAC's latest filing, from -$52000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $124.5 million in Q3 2024 and bottomed at -$24.8 million in Q3 2023.
- Historically, Cash from Financing Activities has averaged $12.6 million across 5 years, with a median of $380500.0 in 2022.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities tumbled 4150.49% — and 2024, when it soared 28779.87%.
- Cartesian Therapeutics' Cash from Financing Activities stood at $612000.0 in 2022, then surged by 2200.82% to $14.1 million in 2023, then sank by 94.44% to $783000.0 in 2024, then sank by 106.64% to -$52000.0 in 2025, then jumped by 30236.54% to $15.7 million in 2026.
- Business Quant data shows RNAC's Cash from Financing Activities at $15.7 million in Q1 2026, -$52000.0 in Q4 2025, and -$38000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 14.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.42 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -6.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -273.15 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Cartesian Therapeutics | 271.98 Mn | 271.98 Mn | - | 50.34 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 50.34 Mn |
| Mar 31, 2026 | 15.67 Mn |
| Dec 31, 2025 | -52,000.00 |
| Sep 30, 2025 | -38,000.00 |
| Jun 30, 2025 | 60,000.00 |
| Mar 31, 2025 | -8.03 Mn |
| Dec 31, 2024 | 783,000.00 |
| Sep 30, 2024 | 124.49 Mn |
| Jun 30, 2024 | 120,000.00 |
| Mar 31, 2024 | 43.03 Mn |
| Dec 31, 2023 | 14.08 Mn |
| Sep 30, 2023 | -24.79 Mn |
| Jun 30, 2023 | -2.59 Mn |
| Mar 31, 2023 | 149,000.00 |
| Sep 30, 2022 | 612,000.00 |
| Jun 30, 2022 | 36.88 Mn |
| Mar 31, 2022 | 1.73 Mn |
| Dec 31, 2021 | 21.16 Mn |
| Sep 30, 2021 | 1.45 Mn |
| Jun 30, 2021 | 8.98 Mn |